The holy grail of minimally invasive surgery is to perform ever more complex procedures through ever smaller openings — ultimately, through a single incision that heals almost invisibly. Intuitive Surgical's da Vinci SP system has brought that goal to clinical reality for a growing list of procedures. Through a single 2.5 cm cannula, the SP deploys three fully articulating instrument arms and a flexible camera — a feat of engineering miniaturization that allows the surgeon to triangulate instruments within a confined anatomical space previously inaccessible to robotic surgery.
How the SP System Works
The da Vinci SP inserts a single 25mm port — roughly the diameter of a quarter — through which three 6mm wristed instruments and a flexible 3D HD camera are deployed. The instruments emerge from the port, fan out within the body cavity, and then articulate at multiple joints to create working triangles within tight spaces. The system is particularly well-suited to anatomy that conventional multi-port robotic surgery struggles to reach: deep within the pelvis, the lateral pharynx, and deep in the rectum.
The surgeon operates from the same da Vinci surgeon console as the multi-port systems, using the same hand-control interface — but with a visual feedback adjustment that compensates for instruments emerging from the same port rather than separate entry points.
FDA-Approved Indications (2026)
- Radical prostatectomy (RP) — most common SP procedure
- Radical cystectomy with urinary diversion
- Partial nephrectomy
- Single-site cholecystectomy
- Transoral robotic surgery (TORS) for oropharyngeal tumors
- Low anterior resection (LAR) for rectal cancer — 2025 approval
- Partial colectomy — 2025 approval
Outcomes Data: SP Prostatectomy vs. Standard Robotic
The most mature SP data is in radical prostatectomy. A 2025 multi-institutional study comparing SP RP (n=847) to multi-port da Vinci RP (n=2,140) found:
- Estimated blood loss: 83 mL (SP) vs 102 mL (MP) — statistically significant
- Operative time: 198 min (SP) vs 178 min (MP) — SP slightly longer
- Positive surgical margin rate: 12.1% (SP) vs 13.4% (MP) — no significant difference
- Hospital stay: 1.0 day (SP) vs 1.0 day (MP) — identical
- Continence recovery at 3 months: 76% (SP) vs 71% (MP) — trending in favor of SP
- Cosmetic satisfaction: 94% (SP) vs 67% (MP) — significantly higher for SP
The data suggests SP surgery is at least equivalent in oncologic and functional outcomes while providing meaningful cosmetic benefits — a clinically meaningful advantage for the growing population of patients who prioritize scar minimization.
The Competition: Medtronic Hugo SP
Medtronic received CE Mark for the Hugo robotic system in 2023 and filed for FDA approval in 2025. A single-port version of Hugo is in development for the US market. Competition in the robotic surgery space — from CMR Surgical's Versius, Johnson & Johnson's Ottava, and Medtronic's Hugo — is driving down system costs and expanding access beyond the academic centers that have historically dominated robotic surgery adoption.
Supply Chain Implications
Single-port surgery requires SP-specific instrument sets, dedicated draping systems, and a different port architecture than standard robotic trays. Facility supply chain managers preparing for SP programs need SP-specific disposable inventory separate from standard da Vinci Xi/X supplies — an inventory management challenge in high-volume robotic programs running multiple platforms.
Conclusion
The da Vinci SP represents the current pinnacle of minimally invasive surgical minimalism — maximum surgical capability through the smallest possible access. As the indication list expands and competing platforms arrive, single-port robotic surgery is moving from niche subspecialty tool to mainstream surgical option for patients who want effective surgery with the least possible external evidence that it happened. Healthcare facilities can find relevant surgical supplies in our catalog.
